# Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population

Study · id `cardio:ct-nct03696940` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03696940](<https://clinicaltrials.gov/study/NCT03696940>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03696940

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 120 participants.

## Technical summary

Registry record NCT03696940. Randomized; single masking; primary purpose treatment. Start 2018-05-28 (actual); primary completion 2019-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT03696940, source copy `cardio:ctgov-nct03696940-2019-02-26`, retrieved 2026-10-31)
- Started: 2018-05-28 (actual) (ClinicalTrials.gov record NCT03696940, source copy `cardio:ctgov-nct03696940-2019-02-26`, retrieved 2026-10-31)
- Primary completion: 2019-03-01 (anticipated) (ClinicalTrials.gov record NCT03696940, source copy `cardio:ctgov-nct03696940-2019-02-26`, retrieved 2026-10-31)
- Completion: 2019-08-31 (anticipated) (ClinicalTrials.gov record NCT03696940, source copy `cardio:ctgov-nct03696940-2019-02-26`, retrieved 2026-10-31)
- Countries: Mexico (ClinicalTrials.gov record NCT03696940, source copy `cardio:ctgov-nct03696940-2019-02-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03696940-2019-02-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
- Condition: Dyslipidemias
- Condition: Cardiovascular Risk Factor
- Intervention (Drug): L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
- Intervention (Drug): Atorvastatin 10mg
- Lead sponsor: Laboratorios Grossman, S.A.
- Lead sponsor class: INDUSTRY
- Collaborator: Instituto Nacional de Salud Publica, Mexico
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 9f92022f26267139525ede7716132152b310332bba1b1b6ba97b7505354c3b16
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
